# Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin

> **NCT02345304** · PHASE1 · WITHDRAWN · sponsor: **Boehringer Ingelheim**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Omeprazole
- **DRUG:** Warfarin
- **DRUG:** BI 1181181
- **DRUG:** Midazolam
- **DRUG:** Omeprazole
- **DRUG:** BI 1181181
- **DRUG:** Midazolam
- **DRUG:** Midazolam
- **DRUG:** Warfarin
- **DRUG:** BI 1181181
- **DRUG:** Digoxin
- **DRUG:** Digoxin

## Key facts

- **NCT ID:** NCT02345304
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-03
- **Primary completion:** 2015-04
- **Final completion:** 2015-05
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02345304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02345304, "Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02345304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*